Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study
-
Published:2024-07
Issue:
Volume:222
Page:175-182
-
ISSN:0002-9149
-
Container-title:The American Journal of Cardiology
-
language:en
-
Short-container-title:The American Journal of Cardiology
Author:
Fath Ayman R.ORCID,
Aglan Mostafa,
Aglan Amro,
Chilton Robert J.,
Trakhtenbroit Anatole,
Al-Shammary Odaye A.,
Oppong-Nkrumah Oduro,
Lenihan Daniel J.,
Dent Susan F.,
Otchere Prince
Reference23 articles.
1. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment;Saleh;Heart Fail Rev,2021
2. Cardiotoxicity of anthracyclines;Cardinale;Front Cardiovasc Med,2020
3. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology;Spallarossa;J Cardiovasc Med (Hagerstown),2016
4. Sodium-glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines;Gongora;JACC Heart Fail,2022
5. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer;Abdel-Qadir;JACC Cardiooncol,2023